Cytokinetics announced FDA approval of MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy in December 2025, with U.S. commercial launch underway and first prescriptions dispensed. The company also received approvals from China's NMPA and European Commission. Cytokinetics reported $1.22 billion in cash and investments as of December 31, 2025, with 2026 guidance of $830-870 million in combined R&D and SG&A expenses. The company expects to report topline results from ACACIA-HCM in Q2 2026 and launch in Germany in Q2 2026.

The global ALS therapeutics market is valued at USD 812 million in 2024 and is projected to reach USD 1,964 million by 2035, growing at an 11.5% CAGR. Growth is driven by innovations in genetic therapies, gene-silencing technologies, improved diagnostics, and increased disease awareness. Key players include Biogen, Ionis Pharmaceuticals, Amylyx Pharmaceuticals, and others developing disease-modifying treatments.

Cytokinetics announced it will report fourth quarter 2025 results on February 24, 2026, followed by a conference call at 4:30 PM ET. The specialty cardiovascular biopharmaceutical company highlighted its approved cardiac myosin inhibitor MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy, with a European Commission decision expected in Q1 2026. The company is also developing omecamtiv mecarbil and ulacamten for various heart failure indications.

Cytokinetics granted stock options to purchase 29,416 shares and 19,825 restricted stock units to 8 employees hired in December 2025 and January 2026 as material inducements to employment. The stock options have an exercise price of $63.44 per share and vest over 4 years, while RSUs vest over 3 years with a 40-40-20 schedule.

Cytokinetics' CEO Robert I. Blum is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company, a specialty cardiovascular biopharmaceutical firm, has FDA-approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy and is advancing a pipeline of cardiac muscle dysfunction treatments.

Tango Therapeutics announced the appointment of Sung Lee, Executive Vice President and CFO at Cytokinetics, to its Board of Directors. Lee brings over 20 years of finance leadership experience from roles at major biopharmaceutical companies including Vir Biotechnology, MorphoSys, Sangamo Therapeutics, and Gilead Sciences. His appointment is intended to support Tango's advancement of its lead program vopimetostat into registrational studies.

Grabar Law Office is investigating shareholder claims against four companies for alleged breaches of fiduciary duties and securities fraud. Cytokinetics faces allegations of misleading statements regarding FDA decisions on its aficamten drug application. Molina Healthcare is accused of failing to disclose adverse medical cost trends and guidance cuts. Synopsys allegedly misrepresented financial performance in its ANSYS acquisition materials, with the stock plunging 35.8% after disappointing Q3 results. WEBTOON Entertainment's class action lawsuit survived a motion to dismiss, with allegations of misleading Monthly Active Users metrics at IPO.

Cytokinetics announced FDA approval of MYQORZO (aficamten), a cardiac myosin inhibitor for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The approval is based on the SEQUOIA-HCM Phase 3 trial, which demonstrated significant improvements in exercise capacity and symptom relief. The drug will be available in the U.S. in the second half of January 2026 and is subject to a REMS program due to heart failure risks. Cytokinetics also received NMPA approval in China and a positive opinion from the European Medicines Agency.

Cytokinetics granted stock options and restricted stock units to 10 new employees in November and December 2025 as a material inducement to their employment, with specific vesting schedules for stock options and RSUs.

Grabar Law Office is investigating potential securities fraud and fiduciary breaches for several publicly traded companies, alleging misleading statements and undisclosed business risks that potentially harmed shareholders.

Foresite Capital Management IV, LLC disclosed a new $25.19 million stake in Cytokinetics, acquiring 458,295 shares, representing 13.8% of its reportable assets as of September 30, 2025.

Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for several publicly traded companies, alleging misleading statements and incomplete disclosures that potentially harmed shareholders.